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Abstract
Introduction: High-flow nasal cannula oxygen (HFNC) and non-invasive ventilation (NIV) have been
widely used in patients with acute hypoxic respiratory failure (AHRF) due to coronavirus disease 2019
(COVID-19). However, the impact of HFNC vs. NIV on clinical outcomes of COVID-19 is uncertain.
Therefore, we performed this meta-analysis to evaluate the effect of HFNC vs. NIV in COVID-19-related
AHRF.
Methods: Several electronic databases were searched through February 10, 2022, for eligible studies
comparing between HFNC and NIV in COVID-19-related AHRF. Our primary outcome was intubation.
The secondary outcomes were mortality, length of hospital stay (LOS), and PaO2/FiO2 ratio changes.
Pooled risk ratio (RR) and mean difference (MD) with the corresponding 95% confidence intervals (CIs)
were obtained using a random-effect model. Prediction intervals (PI) were calculated to indicate the
variance in outcomes that would be expected if new studies were conducted in the future.
Results: Nineteen studies involving 3606 subjects (1880 received HFNC and 1726 received NIV) were
included. There were no differences in intubation (RR 1.01, 95% CI 0.85-1.20, P=0.89) or LOS (MD 0.38
days, 95% CI -0.61, 1.37, P=0.45) between groups with consistent results on the subgroup of RCTs.
Mortality was lower in NIV (RR 0.81, 95% CI 0.66-0.98, P=0.03). However, PI was 0.41-1.59, and
subgroup analysis of RCTs showed no difference in mortality between groups. There was a greater
improvement in PaO2/FiO2 ratio with NIV (MD 22.80, 95% CI 5.30-40.31, P=0.01).
Conclusions: Our study showed that despite the greater improvement in PaO2/FiO2 ratio with NIV, the
intubation and length of hospital stay were similar between HFNC and NIV. Although mortality was
lower with HFNC than NIV, the prediction interval included the null value, and there was no difference in
mortality between HFNC and NIV on a subgroup of RCTs. Future large-scale RCTs are necessary to
prove our findings.
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Introduction
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection, was first discovered in China in December 2019 1. COVID-9 has become a
worldwide pandemic leading to significant morbidity and mortality 1, 2. Acute hypoxic respiratory failure
(AHRF) due to viral pneumonitis is the most common organ failure and the most common cause of
admission to the intensive care unit (ICU) and mortality among patients with COVID-19 3.
During this long COVID-19 pandemic, non-invasive respiratory strategies (NIRS), such as highflow nasal cannula oxygen (HFNC) and non-invasive ventilation (NIV), have gained popularity among
patients with AHRF due to COVID-19 4. These NIRSs might help avoid the need for intubation and
invasive mechanical ventilation and its associated risk 4. NIV includes continuous positive airway
pressure (CPAP) and bi-level positive airway pressure (BPAP) 5. NIV has been widely used in AHRF due
to non-COVID-19 causes, and it effectively decreased the intubation rate 6. HFNC is a relatively new
NIRS used in managing AHRF, and due to its simplicity, it has been recently utilized increasingly in
patients with AHRF and COVID-19 7. HFNC delivers warmed humidified oxygen through nasal cannulae
at high flow rates up to 60 liters/minute 7.
Several studies compared HFNC vs. NIV to determine their effect on clinical outcomes in
subjects with COVID-19. In July 2020, Duan et al.8 published the first study comparing HFNC vs. NIV,
which showed comparable rates of intubation and mortality between the two groups. Since then, many
studies have compared these two NIRSs with conflicting findings7, 9, 10. Although few studies7, 8, 11
revealed that HFNC and NIV were associated with similar clinical outcomes, Gaulton et al.10 showed that
patients who received NIV had a lower intubation rate than HFNC. On the contrary, Nair et al.9 showed
that HFNC was associated with a lower intubation rate than NIV. Due to the uncertainty regarding the
impact of these NIRSs on subjects with COVID-19, we performed this meta-analysis to compare the
effect of HFNC vs. NIV on clinical outcomes of subjects with AHRF associated with COVID-19.
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Methods
Data sources and search strategy
We performed a comprehensive search for published studies indexed in PubMed/MEDLINE,
EMBASE, Cochrane Central Register of Controlled Trials, and preprint servers (medRxiv and Research
Square) from inception to February 10, 2022. Additional articles and preprint versions were searched on
medrxiv.org and researchsquare. We also performed a manual search for additional relevant studies using
references of the included articles. The following search terms were used: (“high-flow nasal cannula” or
“HFNC”), (“non-invasive ventilation” or “NIV” or “CPAP” or “positive pressure ventilation” or
“BiPAP”), and (“COVID” or “COVID-19”). The search was not limited by language, study design, or
country of origin. Supplementary Table 1 describes the full search term used in each database searched.
Eligibility criteria
All studies that performed a direct comparison between HFNC and NIV (either BPAP or CPAP)
were used as first-line NIRS in subjects with AHRF associated with COVID-19 and reported the
following clinical outcomes: intubation, mortality, or length of hospital stay (LOS), were eligible for
inclusion. We excluded single-arm studies, case reports, case series, and reviews.
Data extraction
The following data were extracted from the studies: first author name, publication year, country
of origin, study design, sample size, gender of subjects, mean age, and baseline patient characteristics.
Outcome measures in both groups (HFNC and NIV) were retrieved, including intubation, mortality, LOS,
and the change in oxygenation in the form of partial arterial pressure of oxygen to the fractional inspired
concentration of oxygen ratio (PaO2/FiO2 ratio). We contacted the corresponding authors of studies for
missing or unclear data. We followed the Preferred Reporting Items for Systematic Reviews and Meta-
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Analyses (PRISMA) Statement guidelines to select the final studies 12. Two investigators (AB and OS)
independently performed the search and shortlisted the studies for final review. Discrepancies were
resolved by a third reviewer (KS).
Outcomes of interest
The primary outcome of our study was the intubation rate between HFNC and NIV. The
secondary outcomes were mortality, LOS, and the change in oxygenation (i.e., PaO2/FiO2 ratio) between
HFNC and NIV.
Statistical analysis
We performed a meta-analysis of the included studies using Review Manager 5.3 (Cochrane
Collaboration, Copenhagen, The Nordic Cochrane Centre) and Comprehensive Meta-Analysis (Biostat,
Englewood, USA). The median and interquartile range were converted to mean and SD where applicable
13.

The random-effects model was used to calculate the pooled risk ratio (RR) and mean difference (MD)

with the corresponding confidence intervals (CI) for proportional and continuous variables, respectively.
A P-value <0.05 was considered statistically significant. Where the mean and SD of the change from
baseline to endpoint were not reported in the original studies for PaO2/FiO2 ratio, an imputed value, Corr,
for the correlation coefficient (r) was used to calculate them 14. We performed a sensitivity analysis using
r of 0.4, 0.5, and 0.6 for our meta-analyses, and the results did not significantly change, indicating that our
analyses were robust to this assumption 14. We used r of 0.5 in our meta-analysis 15. The heterogeneity of
the effect size estimates across the studies was quantified using the Q statistic and I2 (P < 0.10 was
considered significant). A value of I2 of 0–25% indicates insignificant heterogeneity, 26–50% low
heterogeneity, 51–75% moderate heterogeneity, and 76–100% high heterogeneity 16. In addition, we also
provided the 95% prediction intervals (PI) for outcomes reported by >10 studies, which indicate the
variance in outcomes that would be expected if future studies were conducted 17, 18. Calculating prediction
intervals were helpful for assessing whether the variation across studies was clinically significant.
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Sensitivity and subgroup analyses
We performed subgroup analysis based on the type of NIV (BPAP or CPAP) and method of NIV
delivery (helmet or mask) if at least three studies reported the outcome. We also performed subgroup
analysis based on the study design (randomized controlled trials [RCTs] vs. observational studies). To
confirm the robustness of our results, sensitivity analysis for intubation and mortality using leave-one-out
meta-analysis was performed to see if it had a significant influence on the meta-analysis result (i.e., jackknife sensitivity analysis).
Bias assessment
The Jadad composite scale was used to assess the methodological quality of the clinical trials
based on randomization, blinding, and withdrawals 19. The scale ranged from 0 to 5 points 19. Studies with
a total score of ≥3 were considered to have a low risk of bias. The Newcastle Ottawa Quality Assessment
Scale (NOS) was used to assess the quality of the observational studies based on the selection of the study
groups, comparability of study groups, and ascertainment of exposure/outcome 20. Studies with total
scores of ≥6 were considered to have a low risk of bias. For outcomes reported by ≥10 studies,
publication bias was assessed qualitatively by visual inspection of the funnel plot and quantitively by
Egger’s regression analysis. Two authors (AB and MM) independently assessed each study for bias.
Discrepancies were resolved by a third reviewer (HA).

Results
Study selection
Our search strategy retrieved a total of 2005 studies. Among these, 41 were eligible for
systematic review. Subsequently, we excluded 22 studies because of single-arm studies reporting either
HFNC or NIV only, lack of appropriate outcome, or presence of non-mutually exclusive groups.
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Eventually, 19 studies7-11, 21-34 met our inclusion criteria and were included in the meta-analysis. Figure 1
shows the PRISMA flow chart that illustrates how the final studies were selected.
Study and subjects’ characteristics
Tables 1 and 2 show the study and subject characteristics of the studies included in the metaanalysis. All the included studies were published between July 2020 and February 2022 and included
hypoxic subjects with COVID-19. Based on country of origin, three studies originated from Italy, four
studies from the United Kingdom, two studies from China, two studies from the United States, two
studies were multinational, one study from Brazil, one from Egypt, one from India, one from Morocco,
one from Portugal, and one from Saudi Arabia. Regarding the design of studies, three9, 21, 33 were RCTs,
and 167, 8, 10, 11, 22-32, 34 were observational cohort studies (13 studies were retrospective cohort, and three
were prospective cohort).
A total of 3606 subjects (1880 received HFNC and 1726 received NIV) were included, with
males representing 66.5% of the total subjects. Six studies applied BPAP, whereas six studies applied
CPAP, and four reported applying both BPAP and CPAP, and three studies did not report whether they
applied BPAP or CPAP. The assessment of the risk of bias is shown in Supplementary Table 2. Among
the observational studies, all studies scored ≥6 on the NOS except one study11, which scored <6, and all
the three RCTs scored ≥ 3 (Supplementary Table 2).
Outcomes of interest
Intubation
Table 2 summarizes the outcomes of the individual studies included in the meta-analysis. Across
the 177-11, 21-23, 25-28, 30-34 studies that reported the intubation rate, 46% of subjects who received HFNC
required intubation compared to 37.8% in subjects who received NIV. The intubation rate was similar
between HFNC and NIV groups (RR 1.01, 95% CI 0.85-1.20, P = 0.89, I2 = 68%, Figure 2A). The 95%
PI for estimated to be 0.58-1.76. The results remained consistent on subgroup analysis of BPAP (RR 1.06,
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95% CI 0.81-1.38, P = 0.69, I2 = 45%) and CPAP (RR 1.02, 95% CI 0.73-1.42, P = 0.90, I2 = 63%)
(Figure 2B). Consistent results were obtained on subgroup analysis based on the method of NIV delivery
(mask or helmet) (Figure 2C).
The results were consistent on subgroup of RCTs (RR 1.09, 95% CI 0.67-1.78, P = 0.72, I2 =
79%, Figure 2D). No significant difference in rates of intubation was observed on subgroup analysis for
peer-reviewed studies (RR 1.06, 95% CI 0.89-1.28, P = 0.51, I2 = 71%, Supplementary Figure 1A) and
high-quality studies (RR 1.01, 95% CI: 0.84-1.21, P = 0.91, I2 = 70%, Supplementary Figure 1B). A
leave-one-out sensitivity analysis showed consistent results (Supplementary Figure 1C). However,
sensitivity analysis on excluding the study by Wendel-Garcia et al. in 202232 resulted in I2 = 34% without
significant change in overall intubation rate (Supplementary Figure 1D).
Mortality
Seventeen studies7-10, 21, 23-34 reported the mortality rate. The mortality rate was 28.2% in the
HFNC group compared to 34.6% in the NIV group. Overall, HFNC was associated with lower mortality
compared to NIV (RR 0.81, 95% CI 0.66-0.98, P = 0.03, I2 = 68%, Figure 3A); however, 95% PI was
estimated to be 0.41-1.59. Subgroup analysis of peer-reviewed studies revealed favored HFNC over NIV
in mortality (RR 0.80, 95% CI 0.65-0.99, P = 0.04, I2 = 69%, Figure 3B). However, 95% PI was
estimated to be 0.39-1.65. Furthermore, subgroup analysis of RCTs revealed no significant difference
between HFNC and NIV in mortality (0.92, 95% CI 0.65-1.29, P = 0.62, I2 = 42%, Figure 3C). On
subgroup analysis based on the type of NIV, HFNC and CPAP were comparable in mortality (RR 0.89,
95% CI 0.65-1.21, P = 0.46, I2 = 69%, Figure 3D); however, HFNC was associated with a lower mortality
compared to BPAP (RR 0.63, 95% CI 0.48-0.84, P = 0.001, I2 = 0%, Figure 3D). Nonetheless, the
subgroup difference between the types of NIV (BPAP and CPAP) was not statistically significant (P =
0.28, Figure 3D). Furthermore, subgroup of RCTs comparing HFNC and BPAP showed no difference in
mortality (RR 0.78, 95% CI 0.47-1.29, P = 0.33, I2 = 35%, Figure 3C).
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Subgroup analysis based on the method of NIV delivery (mask or helmet demonstrated no
significant difference in mortality between HFNC and NIV (Supplementary Figure 2A). A leave-one-out
sensitivity analysis showed inconsistent findings in mortality between the two groups (Supplementary
Figure 2B). Removal of either one of these studies (Franco et al., Ghani at el., Nair et al., Rodrigue Santos
et al., Wedel-Garcia et al.) moved the overall effect to be non-significant between HFNC and NIV
(Supplementary Figure 2B).
Length of hospital stay
Eight studies9, 21, 23, 27, 30-34 reported the LOS. There was no significant difference with regards to
the length of hospital stay (MD 0.38 days, 95% CI -0.61, 1.37, P = 0.45, I2 = 0%, Figure 4A). Subgroup
of RCTs showed consistent results (MD 1.16, 95% CI -0.26, 2.57, P = 0.11, I2 = 0%, Figure 4B).
Changes in oxygenation (i.e., PaO2/FiO2 ratio)
Five studies7-9, 21, 22 reported the changes in oxygenation pre and post NIRS therapy in the form of
PaO2/FiO2 ratio. NIV was associated with a greater improvement in PaO2/FiO2 ratio compared to HFNC
(MD 22.80, 95% CI 5.30, 40.31, P = 0.01, I2 = 48.1%, Figure 5A). Subgroup of RCTs demonstrated
consistent findings (MD 35.09, 95% CI 7.88, 62.31, P = 0.01, I2 = 63.5%, Figure 5B).

Quality and publication bias assessment
Quality assessment scores of the RCTs and observational studies are summarized in
Supplementary Table 2. There was a low risk of bias for 18 studies7-10, 21-34, while the risk of bias for one
study was high11, as shown in Supplementary Table 2. The funnel plots for intubation and mortality
appeared symmetric by visual inspection (Supplementary Figure 3), and Egger’s regression analysis did
not show evidence of publication bias (P = 0.19 and P = 0.45 for the intubation and mortality rates,
respectively).
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Discussion
Our meta-analysis shows no significant difference in the intubation rate and length of hospital
stay between HFNC and NIV despite greater improvement of PaO2/FiO2 ratio with NIV. Although
mortality was lower overall in HFNC than in NIV (especially BPAP), subgroup analysis of RCTs
revealed no significant difference in mortality between HFNC and NIV.
In the current prolonged COVID-19 pandemic era, many COVID-19 patients developed AHRF
with increasing demand for respiratory support with intubation and mechanical ventilation. However,
there is a shortage of human and medical resources, and the mortality rates are high among intubated
patients with COVID-19, which may reach up to 67% 35. Therefore, NIRSs, such as HFNC and NIV, have
been widely implemented to avoid the need for endotracheal intubation and invasive mechanical
ventilation among patients with AHRF due to COVID-19 failing on conventional oxygen therapy.
NIV is the first line NIRS to treat patients with hypercapnic AHRF due to chronic obstructive
pulmonary disease (COPD) 36. However, the use of NIV for non-hypercapnic AHRF without prior
chronic respiratory disease (de novo AHRF) as in COVID-19 remains debatable 37. NIV should
theoretically improve lung oxygenation and gas exchange in AHRF compared to HFNC because it
provides a higher positive end-expiratory pressure (PEEP) 38. However, not all patients can tolerate NIV
due to adverse events, such as claustrophobia, facial pressure ulcers, and eye irritation 39, 40. Given the
high rates of intolerability, especially with mask NIV, HFNC is becoming the first line NIRS in patients
with COVID-19 failing on conventional oxygen therapy in many hospital settings and has been
recommended in the surviving sepsis campaign (SSC) guidelines on COVID-19 41. SSC guidelines
recommended using HFNC over NIV as the first line NIRS based on indirect data in an RCT comparing
HFNC with NIV in patients with non-hypercapnic AHRF unrelated to COVID-19 42. That RCT showed
that HFNC was associated with a lower mortality rate at 90 days (hazard ratio 2.50, 95% CI 1.31–4.78)
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but did not significantly decrease the intubation rate (40% intubation rate in HFNC group vs. 50% in NIV
group, P = 0.18) 42. Another meta-analysis by Ni et al.43 comparing HFNC with NIV demonstrated that
HFNC decreased the intubation rate among patients with AHRF not related to COVID-19 without
significantly improving mortality or ICU length of stay.
Due to the lack of clear evidence, few studies have recently evaluated the effectiveness of HFNC
in comparison to NIV on the clinical outcomes of subjects with COVID-19-related AHRF8-11. However,
the findings of these studies were conflicting. A study by Franco et al.23 showed comparable rates of
intubation and mortality between HFNC and NIV. On the other hand, in some studies9, 21 HFNC was
favored over NIV regarding intubation rate, while others10, 11 favored NIV over HFNC regarding
intubation rate. Given the contradicting results of the studies in the literature, we conducted this metaanalysis to provide the first comprehensive evaluation and comparison of HFNC and NIV to address
critical knowledge gaps in the management of COVID-19.
In this meta-analysis, we found greater improvement in PaO2/FiO2 ratio with NIV compared to
HFNC, which was similar to the findings of Grieco et al.11, that showed a higher mean PaO2/FiO2 ratio in
the NIV group compared to the HFNC group with an MD of 50 (95% CI 39-61). However, there was no
significant difference between the two groups in the intubation rate. Our overall study results were in line
with the study by Franco et al.23, which revealed a comparable intubation rate between HFNC and NIV
groups (28.8%, 25.8%, respectively). We believe that despite the improvement in PaO2/FiO2 ratio being
statistically significant, the level of improvement in the PaO2/FiO2 ratio was relatively trivial clinically
(MD of 22.8 in favor of NIV), which might not be enough to translate into improvement in the clinical
outcomes in these patients. In addition, our study results were consistent with Franco et al.23, which
showed no difference in LOS (mean 19.2±13.3 days and 20.4±13.2 days) between HFNC and NIV
groups, respectively. Subgroup analysis based on the type of NIV (helmet vs. mask) showed similar
intubation rates between HFNC and NIV.
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On overall analysis, HFNC was associated with lower mortality than NIV (especially with
BPAP), but 95% prediction interval included the null value and subgroup difference between the type of
NIV was not statistically significant. In addition, when subgroup analysis is restricted to RCTs, there was
no significant difference in mortality between HFNC and NIV, including BPAP. Notably, the reduction in
mortality with HFNC compared to NIV was driven by observational studies31, 32, which are more
vulnerable to methodological problems such as selection and confounding biases. This difference in
mortality between HFNC and NIV (including BPAP) could be attributed to BPAP being applied to sicker
patients compared to HFNC. Some observational studies that showed lower crude mortality rate in the
HFNCO found that the difference in mortality between groups disappeared after adjusting for
confounders such as age, baseline PaO2/FiO2, and the number of comorbidities 23, 30, which support our
study findings. Therefore, more RCTs with controlling for are needed to evaluate the impact of NIRS on
clinical outcomes of patients with COVID-19. In addition, the vast majority of the studies did not report
the details of awake prone positioning (APP) between the two groups, which could also have influenced
the mortality outcome in favor of HFNC 23. HFNC group could tolerate and implement APP better than
the NIV group. A recent meta-analysis has shown that APP reduced mortality without significant change
in intubation or length of hospital stay 44. For instance, in an RCT by Grieco et al.21, the use of APP was
not standardized, and APP was implemented more frequently in patients in the HFNC group. Lastly, the
higher mortality rate in the NIV group, especially with BPAP, could be attributed partly to the increased
risk of volutrauma in the NIV group due to higher tidal volume 45.
Our results regarding intubation and mortality were in line with the findings of single-arm
studies. Demoule et al.46 showed that 25% of patients who used HFNC required intubation, and 56% died.
Kofod et al. showed a 43% intubation rate and 29% mortality among patients who received CPAP 47.
However, there is a need for future RCTs for better evaluation of such an important topic. There are
several registered clinical trials still in the recruitment stage evaluating the effect of HFNC vs. NIV on the
clinical outcomes of COVID-19, such as RCT by Tverring et al.48 (NCT04395807) and (NCT04715243).
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These trials are expected to provide more solid evidence regarding the role of HFNC and NIV among
subjects with AHRF and COVID-19. However, it will be difficult to include subjects with a history of
COPD or chronic hypercapnic respiratory failure as this will violate the concept of equipoise since NIV is
the NIRS of choice in these patients 36, 49. For instance, Tverring et al.48 will exclude subjects with
underlying COPD stage III/IV.
Several limitations of this study should be acknowledged. First, the meta-analysis included
mainly observational studies, which are vulnerable to confounding and selection biases. Therefore, further
large-scale RCTs are warranted to confirm our findings. Second, even though the random-effects model
was used in our analysis, there was moderate to high heterogeneity noted in the measurement of our
outcomes, such as intubation and mortality. This might be driven by differences in patient characteristics
(such as the presence of COPD) and COVID-19 severity, inconsistent follow-up duration, the variations
in the concomitant drugs used for COVID-19 in the included studies. Subsequent subgroup/sensitivity
analyses and calculation of prediction intervals were performed to help explain the significant
heterogeneity in the outcomes of intubation and mortality. Third, the lack of patient-level data did not
allow to control for the presence of COPD/chronic respiratory failure among the subjects in the included
studies, which might introduce potential bias since it is well-known that NIV is the standard-of-care NIRS
in patients with hypercapnic AHRF due to COPD 36. Only one trial by Nair et al.9 excluded subjects with
COPD or chronic respiratory failure. However, the rest of the studies did not control for the presence of
COPD in the included patients. Therefore, our findings cannot be generalized to subjects with COPD or
chronic respiratory failure. Fourth, we completed the analysis before pre-registration without PROSPERO
registration number, which should be avoided in our future meta-analysis. Finally, we were unable to
evaluate the proportion of subjects performing awake prone positioning sessions in each group in most
studies due to limited reported data. We also could not evaluate the tolerability and complications of NIV
vs. HFNC.
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Despite the limitations, our study has significant strengths. First, we included a total of 19 studies
with over 3600 subjects with COVID-19. To our knowledge, this is the first meta-analysis comparing the
effect of HFNC vs. NIV on clinical outcomes in subjects with COVID-19. The results were consistent for
intubation on sensitivity analysis and subgroup analysis based on the study design (RCTs vs.
observational studies) and the method of NIV delivery (helmet vs. mask). Furthermore, the majority of
the included studies were of high quality based on quality assessment. Finally, we provided prediction
intervals for mortality and intubation, which further accounts the uncertainty for the effect that would be
expected in a new study addressing the same association.
Conclusions
In summary, our study showed that despite greater improvement in PaO2/FiO2 ratio with NIV,
the intubation and length of hospital stay were similar between HFNC and NIV. Although mortality was
lower with HFNC than NIV, the prediction interval included the null value, and there was no difference in
mortality between HFNC and NIV on a subgroup of RCTs. Future large-scale RCTs are necessary to
prove our findings.
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Figure legends
Figure 1: PRISMA flow diagram for the selection of studies.
Figure 2: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding the
intubation rate. (B) Subgroup analysis based on the type of ventilation (CPAP vs. BPAP) for the
intubation rate. (C) Subgroup analysis based on the method of non-invasive ventilation (helmet vs. mask).
(D) Subgroup analysis of randomized controlled trials for the intubation rate.
Figure 3: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding
mortality. (B) Subgroup analysis of peer-reviewed studies for mortality. (C) Subgroup analysis of
randomized controlled trials for mortality with subgroup based on the type of non-invasive ventilation
used (BPAP vs. CPAP). (D) Subgroup analysis based on the type of ventilation (CPAP vs. BPAP) for
mortality.
Figure 4: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding the
length of hospital stay. (B) Subgroup analysis of randomized controlled trials for the length of hospital
stay.
Figure 5: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding the
change in PaO2/FiO2 ratio. (B) Subgroup analysis of randomized controlled trials for the change in
PaO2/FiO2 ratio.
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Table 1: Study characteristics of the included studies.
Study, year

Study
design

Country

Total n
(HFNC/NIV)

Male, n (%)

Age,
mean±SD,
years

Subject
location &
APP
(HFNC/NIV)

Type of NIV
(method of delivery)

HFNC/NIV
duration, median
(IQR) or
mean±SD

Follow-up
duration

Alharthy,
2020
Alkouh,
2022

RC

30 (15/15)

25 (83.3)

46.3±15

ICU (15/6)

CPAP (helmet)

233 (162/71)

166 (71.2)

65.8±13.5

ICU (NR)

NR

9 (7–11) / 8 (6–
11)
NR

NR

RC

Saudi
Arabia
Morocco

Costa, 2022

RC

Brazil

37 (23/14)

26 (70.3)

68.8±18.5

BiPAP (mask)

NR

NR

Duan, 2020

RC

China

36 (23/13)

24 (66.7)

59.6±15.6

BPAP (mask)

RC

Italy

670 (163/507)

464 (69.3)

68.3±13.3

Gaulton,
2020
Ghani, 2021

RC

USA

59 (42/17)

28 (47.5)

60±15

ICU (NR)

BPAP & CPAP
(mask & helmet)
CPAP (helmet)

3.6 (1.6-8.4) / 6.8
(4.5-10)
NR

NR

Franco, 2020

ICU and Ward
(NR)
ICU & Ward
(NR)
Ward (NR)

NR

NR

PC

UK

130 (35/95)

89 (68.5)

60 (median)

Ward (NR)

CPAP (mask)

NR

NR

Grieco, 2021

RCT

Italy

109 (55/54)

88 (80.7)

63.6±11.1

ICU (NR)

BPAP (helmet)

NR

60 days

Menga, 2021

PC

Italy

85 (24/61)

NR

NR

ICU (NR)

NR

NR

Nadeem,
2021
Nair, 2021

RC

UK

100 (44/56)

61 (61)

76.5

Ward (NR)

BPAP (mask &
helmet)
BPAP & CPAP (NR)

NR

NR

RCT

India

109 (55/54)

79 (72.5)

56.4±12.9

ICU (NR)

NR

NR

Pearson,
2021
Perkins,
2021
Rodrigues
Santos, 2022
Shoukri,
2021
Sykes, 2021

RC

USA

62 (31/31)

38 (61.3)

64.5±15.9

ICU (NR)

NR

NR

CPAP (mask)

3.7±4.1 / 3.5±4.6

30 days

15.4±13.6 /
14.7±11.3
5.53±1.11 /
5.86±1.10
3 (1-14) / 3 (1-24)

NR

BPAP (mask &
helmet)
CPAP (helmet)

RCT

UK

798 (418/380)

532 (66.7)

57.2±12.8

RC

Portugal

190 (139/51)

130 (68.4)

66.7±11.8

ICU and Ward
(243/207)
Ward (47/18)

RC

Egypt

63 (37/26)

40 (63.5)

66.44±8.86

ICU (NR)

BPAP & CPAP
(mask)
BPAP (mask)

PC

UK

140 (71/69)

89 (63.7)

71.2±11.1

Ward (NR)

CPAP (mask)

NR

30 days

NR
NR

Respiratory Care

WendelGarcia, 2021
WendelGarcia, 2022
Zhao, 2021
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RC

Multicentric

174 (87/87)

127 (73)

64.9±15.4

ICU (NR)

BPAP & CPAP (NR)

NR

NR

RC

Multicentric

540 (439/101)

365 (67.6)

61.9±11.9

ICU (NR)

BPAP & CPAP (NR)

NR

90 days

RC

China

41 (17/24)

28 (68.3)

66.6±12.3

NR (NR)

NR

NR

NR

Abbreviations: APP: awake prone positioning, BPAP: bi-level positive airway pressure, CPAP: continuous positive airway pressure, HFNC: high-flow nasal
cannula, n: sample size, ICU: intensive care unit, IQR: interquartile range, NIV: non-invasive ventilation, NR: not reported, PC: prospective cohort, RCT:
randomized controlled trials, RC: retrospective cohort, SD: standard deviation, UK: United Kingdom, USA: United States
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Table 2: Subject characteristics and outcomes of the included studies in the meta-analysis.
Study, year

BMI,

SOFA score

PaCO2,

DM

COPD

Mortality

Intubation

LOS,

PaO2/FiO2

median

(HFNC/NIV)

mean±SD or

(HFNC

(HFNC

(HFNC/NIV)

(HFNC/NIV)

mean±SD,

(baseline/post-treatment),

,

median

/NIV)

/NIV)

days

median (IQR) or mean±SD

(HFNC/NIV)

HFNC

NR

213

(IQR)

or

median

mean±SD,

(IQR)

kg/m2

mean±SD

or

)

Alkouh, 2022

NIV

mmHg
(HFNC/NIV

(HFNC/NIV

Alharthy, 2020

(IQR),

ratio

)

24 (20–29) /

9 (8-10) / 9

24 (20–29)

(8-10)

27.59±4.67

NR

7/5

NR

NR

2/3

241)

NR

NR

50/19

NR

79/34

80/33

NR

4 (0.7-2) / 5

NR

9/5

4/5

5/5

16/8

23

(199–
/

380

211 (198–235)
/

377 (344–

(352–421)

422)

NR

NR

NR

NR

/
27.49±4.93
Costa, 2022

29.4±5.5
32.4±4.7

/

(2.2-10)

(14.7-

32.5) / 20.5
(12-35)
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Duan, 2020

NR

4±2 / 4±1

Franco, 2020

NR

2.5±0.9 / 3.5

Gaulton, 2020

35.8±9.0

36±5 / 35±4

4/0

1/0
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1/1

4/2

19.2±13.3

196±48

/

/

165±48

224±92

202±65

166±65 / NR

146.5±82.6

NR

32/93

9/37

26/154

47/131

NR

NR

13/8

NR

8/1

22/3

NR

NR

NR

NR

NR

(1.8)
/

NR

20.4±13.2

/

/

NR

34.8±7.8
Ghani, 2021

NR

NR

NR

NR

NR

12/54

6/44

NR

Grieco, 2021

28 (26-31) /

2 (2-3) / 2 (2-

34 (32-37) /

10/13

NR

14/13

28/16

26.6±23.6

27 (26-30)

3)

34 (31-37)

NR

NR

32 (28-35) in

Menga, 2021

NR

/

102±33.5

/

104.3±32

21.7±12.2

138±46

188±73

NR

NR

NR

NR

15/37

NR

NR

NR

35/37

NR

NR

17/16

NR

16/25

15/25

9.7±4.6

/

both groups
Nadeem, 2021

NR

NR

NR

Nair, 2021

NR

NR

34

(26.3-

38.5)

/

32

NR
/

112.5±36

NR
/

115.5±42.04 /

9±4.6

134.7±78.8

157.6±82.6

NR

NR

(26.0-43.3)
Pearson, 2021

29.1

(23.5-

38.6)

/

NR

NR

14/18

9/4

18/15

15/17

NR

NR

33 (30-36) /

98/86

NR

86/72

169/126

18.3±20

32

(27.6-38.8)
Perkins, 2022

NR

33 (30-36.8)

16.4±17.5

/

186.3±97.5
NR

/

182.8±94.7
NR

/
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Rodrigues

28.2±5.7

Santos, 2022

28.2±5.7

Shoukri, 2021

NR

/

NR

3.02±0.94

/

2.69±0.77

NR

47/18

8/4

38/31

23/8

15.4±13.6

14.7±11.3

NR / NR

34.67±3.69 /

12/9

3/3

1/1

4/3

NR

191.08±37.83

190.38±42.47 /

/

241.53±44.43

35.03±3.99

225.67±44.33
Sykes, 2021

NR

NR

NR

19/21

16/20

44/40

NR

NR

75.9±40.3

/

77.3±38.2 / NR

NR
Wendel-Garcia,

27 (25-32) /

6 (3-7) / 6 (4-

2021

26 (24-29)

7)

Wendel-Garcia,

28 (26-31) /

NR

2022

28 (26-31)

Zhao, 2021

NR

NR

NR

26/17

91/21

10/7

32/7

17/32

106/37

45/43

307/89

13 (6-24) / 17

126 (79-169) /

135 (97-168) /

(8-26)

NR

NR

13 (7-26) / 13

NR

NR

NR

NR

(8-24)
NT

NR

NR

NR

9/14

12/16

NR

Abbreviations: BMI: body mass index, COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus, HFNC: high-flow nasal cannula, NIV: non-invasive
ventilation, IQR: interquartile range, n: sample size, NR: not reported, SOFA: sequential organ function assessment, SD: standard deviation.
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Figure 1: PRISMA flow diagram for the selection of studies.
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Figure 2: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding the
intubation rate. (B) Subgroup analysis based on the type of ventilation (CPAP vs. BPAP) for the intubation
rate. (C) Subgroup analysis based on the method of non-invasive ventilation (helmet vs. mask). (D)
Subgroup analysis of randomized controlled trials for the intubation rate.
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Figure 3: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding
mortality. (B) Subgroup analysis of peer-reviewed studies for mortality. (C) Subgroup analysis of
randomized controlled trials for mortality with subgroup based on the type of non-invasive ventilation used
(BPAP vs. CPAP). (D) Subgroup analysis based on the type of ventilation (CPAP vs. BPAP) for mortality.
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Figure 4: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding the
length of hospital stay. (B) Subgroup analysis of randomized controlled trials for the length of hospital stay.
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Figure 5: (A) Forest plot comparing high-flow nasal cannula and non-invasive ventilation regarding the
change in PaO2/FiO2 ratio. (B) Subgroup analysis of randomized controlled trials for the change in
PaO2/FiO2 ratio.
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